#USA #Bethlehem #Bioreactor #ABEC #ATB™-2100

ABEC Launches the ATB™-2100 Platform for Advanced Therapies

On November 5, 2026, ABEC, a global leader in biopharmaceutical solutions, announced the introduction of their ATB™-2100 Advanced Therapy Bioreactor. This state-of-the-art technology aims to revolutionize the manufacturing of advanced therapies through its innovative features.

Meeting the Growing Demand for Cell Therapy

The ATB™-2100 is a cutting-edge, single-use platform designed specifically for cell expansion, catering to the soaring demand in the cell and gene therapy sectors. As the industry evolves, scalable and reproducible production methods have become paramount. The ATB™-2100 addresses these needs by offering a fully automated and enclosed system, ensuring optimal conditions from preclinical development through to commercial production.

Unmatched Process Control and Scalability

One of the standout features of the ATB™-2100 is its unparalleled process control. This bioreactor utilizes a network of hollow-fiber perfusion membranes created by ABEC to deliver nutrients and gases continuously while simultaneously removing metabolic waste. By mimicking the human circulatory system, it fosters a low-shear environment conducive to cell growth, leading to exceptionally high cell densities and viabilities.

Unlike other cell expansion technologies that necessitate redesigning processes during scaling, the ATB™-2100 maintains a consistent membrane surface-to-volume ratio across bioreactor volumes from 200 ml to 10 l. This consistency allows for seamless scalability, meaning that conditions developed in early phases can be directly applied to commercial production, significantly shortening development timelines and minimizing risks associated with technology transfer.

Overcoming Industry Challenges

As Scott Pickering, CEO of ABEC, stated, "Cell and gene therapies face substantial hurdles in development and manufacturing that limit scalability, escalate costs, and slow down commercialization. The ATB™-2100 overcomes these obstacles, marking another innovative advancement by ABEC." This statement reflects the urgent need for advanced solutions in an ever-evolving scientific landscape.

Conclusion

With the introduction of the ATB™-2100, ABEC stands at the forefront of biopharmaceutical manufacturing innovation. This platform not only enhances productivity but also aims to reduce overall costs, enabling companies to bring life-changing therapies to market more efficiently. For those interested in learning more about the ATB™-2100, further details can be accessed on ABEC’s official website or by contacting their customer service directly.

The ATB™-2100 is set to become a game changer in the industry, demonstrating ABEC’s commitment to facilitating the creation of advanced therapy solutions that can significantly impact patient care and treatment outcomes.